Clinical Trials in France / NCT04888364
Recruiting
Observational
French Parkinson's Disease Cohort - NS-PARK
NCT04888364 · tracked via the Priya Life Science France tracker
Condition(s) studied
Parkinson Disease
Study summary
The aim of NS-PARK cohort are to describe the natural history of Parkinson's disease (PD), and to propose patients stratification models based on PD pathophysiological mechanisms. Patients are included at all PD expert centers in France. Standardized demographic, diagnosis, motor and non-motor symptoms evaluation, and treatment information are collected, and clinical data are updated at each visit of the patient at the center. A blood sampling is perform at baseline for genetic testing and implement an associated biocollection.
Eligibility
Inclusion Criteria:
* Diagnosis of Parkinson's disease according to UK PD brain bak criteria
* OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom
* OR Subjects at risk of PD defined as :
No symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015)
AND for all participants
* Affiliated to social security
* Age \> 10 years
Exclusion Criteria:
* Subject under legal protection
* Subject who do not consent to the research
* for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment
Primary outcome measure(s)
- Disease progression — through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Hoehn and Yahr score change - Motor and non-motor complications — through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Occurence of motor (dyskinesia or motor fluctuations) or non-motor (dementia, dysautonomia, behavioral or psychiatric disorders, sleep disorders, falls, ...) complication - Modification of antiparkinsonian treatment doses — through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Modification of antiparkinsonian treatment during follow-up will be measured as levodopa equivalent daily doses
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre 01 Paris | Paris | France | Recruiting |
More Institut National de la Santé Et de la Recherche Médicale, France trials in France
Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease
Active, not recruiting
Arterial Stiffness as a Tool to Investigate Adherence in Resistant Hypertension
Active, not recruiting
Other trials for the same condition
Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04888364 on ClinicalTrials.gov ↗ ← All trials in France